Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatmentVince Biemans, Gerard Dijkstra, Andrea E. van der Meulen‐de Jong et al.|Alimentary Pharmacology & Therapeutics|2020Cited by 129
Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registryVince Biemans, Jasmijn A M Sleutjes, Annemarie C. de Vries et al.|Alimentary Pharmacology & Therapeutics|2020Cited by 87